# Study of Intravenous ZMA001 in Healthy Subjects

> **NCT05967299** · PHASE1 · RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 96 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension PAH

## Interventions

- **OTHER:** Placebo Cohort 1 (1.5 mg/kg/dose) only
- **DRUG:** ZMA001 (BC-NKA-20008)

## Key facts

- **NCT ID:** NCT05967299
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-27
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-11-30
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05967299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05967299, "Study of Intravenous ZMA001 in Healthy Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05967299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*